Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.
The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.
While revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。